News

Article

Visiox Pharmaceuticals announces merger with Ocuvex Therpeutics

Author(s):

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

(Image Credit: AdobeStock/Ratana21)

(Image Credit: AdobeStock/Ratana21)

Visiox Pharmaceuticals Inc announced it has entered into a definitive merger agreement with Ocuvex Therapeutics Inc.

According to a news release, Ocuvex, a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders, has a pipeline of near-term ophthalmic medicines.1

The companies noted the strategic combination will position the newly combined entity as a potential leader in the eye care sector with a portfolio of ophthalmic medicines.

Visiox's products include omidenepag isopropyl ophthalmic solution (Omlonti), licensed by Visiox from Santen Pharmaceuticals a year ago. Another, PDP-716 (brimonidine) 0.35%, is the next closest to the market. It is a once-daily solution that the company has been hoping to launch in early 2025. It also has SDN-037 (difluprednate) 0.04%, which will grow Ocuvex's market presence and accelerate the commercialization of these therapeutics.1

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

"The combination of Visiox and Ocuvex makes for a perfect match," Ryan S. Bleeks, CEO of Visiox, said in the news release. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."

Reference:
  1. Visiox Pharmaceuticals, Inc. Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc. Prnewswire.com. Published August 19, 2024. Accessed August 19, 2024. https://www.prnewswire.com/news-releases/visiox-pharmaceuticals-inc-announces-transformative-merger-with-ocuvex-therpeutics-inc-302224689.html
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
© 2024 MJH Life Sciences

All rights reserved.